Indoco Remedies Limited (Indoco) proudly announces that its Clinical Research Organisation, AnaCipher, has successfully completed a comprehensive 5-day inspection by the USFDA. The inspection took place from March 3 to March 7, 2025, at its Hyderabad facility.
Conducted by investigators from the Bioresearch Monitoring Program (BIMO) and the Office of Study Integrity & Surveillance (OSIS), the inspection thoroughly evaluated both clinical and bioanalytical phases of three Bioavailability and Bioequivalence (BA/BE) studies submitted by clients to the USFDA.
At the conclusion of the inspection, one Form 483 was issued, which the company is addressing within the stipulated timeframe.
Aditi Kare Panandikar, Managing Director of Indoco Remedies Limited, stated, “This is an exciting step in our journey of excellence and a validation of our adherence to applicable regulations and maintaining the highest standards in delivering quality services to our clients.”
In the meantime, Indoco Remedies’ stock opened today at ₹237.90, reaching a high of ₹238.45 and a low of ₹227.01. The stock remains well below its 52-week high of ₹387.55 but above its 52-week low of ₹190.00.
